CYTOKINETICS INC (CYTK) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 36 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026after close 35 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Tue, May 5, 2026after close 35 8-K
Q4 FY2025Tue, Feb 24, 2026after close 55 8-K
Q3 FY2025Wed, Nov 5, 2025after close 36 8-K
Q2 FY2025Thu, Aug 7, 2025after close 38 8-K
Q1 FY2025Tue, May 6, 2025after close 36 8-K
Q4 FY2024Thu, Feb 27, 2025after close 58 8-K

What they guided beta

Q3 FY2026 "Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027 ~$1.6 Billion in Cash, Cash Equivalents and Investments as of September 30, 2026 SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2026." exhibit
Q3 FY2026 "We expect to launch MYQORZO in the United Kingdom in Q4 2026 and in additional countries in 2027." exhibit
Q3 FY2026 "We expect to file a Supplemental New Drug Application (NDA) for nHCM in Q4 2026 and a Type II Variation in the European Union in early 2027." exhibit
Q3 FY2026 "We expect to present topline data in early 2027." exhibit
Q3 FY2026 "We expect enrollment to continue through 2027. ulacamten (cardiac myosin inhibitor)" exhibit
Q2 FY2026 "Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026" exhibit
Q2 FY2026 "Submitted 10 Health Technology Assessment (HTA) dossiers to support market access across Europe and expect to launch in more than five additional markets by the first half of 2027." exhibit
Q2 FY2026 "The primary results from ACACIA-HCM will be presented in a Hot Line Session at the European Society of Cardiology (ESC) Congress in August 2026." exhibit
Q2 FY2026 "We expect to file a Supplemental NDA for nHCM in Q4 2026." exhibit
Q2 FY2026 "We expect to complete trial conduct in Q3 2026. o Continued conduct of CAMELLIA-HCM, a Phase 3 clinical trial of aficamten in Japanese patients with oHCM." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CYTK
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CYTK

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

CYTK earnings date badge

HTML

<a href="https://veritasdata.dev/company/CYTK/"><img src="https://veritasdata.dev/embed/CYTK.svg" alt="CYTK earnings date" width="240" height="56"></a>

Markdown

[![CYTK earnings date](https://veritasdata.dev/embed/CYTK.svg)](https://veritasdata.dev/company/CYTK/)

Script

<script async src="https://veritasdata.dev/embed/CYTK.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CYTK"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.